GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance

Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow

(2016) Eunsohl Lee et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

(2016) Mihalis S. Kariolis et al.   JOURNAL OF CLINICAL INVESTIGATION

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling

(2016) Cai M. Roberts et al.   Scientific Reports

AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective

(2015) Samuel H. Myers et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells

(2015) Alastair H. Davies et al.   Oncotarget

Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells

(2014) Kinga Pénzes et al.   CANCER BIOLOGY & THERAPY

Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression

(2014) Jennifer L. Yori et al.   CANCER RESEARCH

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

(2014) Nobuaki Ochi et al.   EXPERIMENTAL CELL RESEARCH

Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation

(2014) Wen-I Tsou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer

(2014) Masaki Shiota et al.   PROSTATE

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy

(2014) Robert Torka et al.   NEOPLASIA

Evaluation of Tyro3 Expression, Gas6-Mediated Akt Phosphorylation, and the Impact of Anti-Tyro3 Antibodies in Melanoma Cell Lines

(2013) Stephen J. Demarest et al.   BIOCHEMISTRY

Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin  1/Src/Akt-Driven Bypass Signaling

(2013) R. Kanda et al.   CANCER RESEARCH

c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met

(2012) L. P. Stabile et al.   CLINICAL CANCER RESEARCH

Axl is essential for VEGF-A-dependent activation of PI3K/Akt

(2012) Guo-Xiang Ruan et al.   EMBO JOURNAL

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

(2012) A Astanehe et al.   ONCOGENE

Cross-Phosphorylation, Signaling and Proliferative Functions of the Tyro3 and Axl Receptors in Rat2 Cells

(2012) Jessica E. Brown et al.   PLoS One

An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis

(2011) R Lara et al.   ONCOGENE

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification

(2011) A H Davies et al.   ONCOGENE

Y-Box Binding Protein-1 Induces the Expression ofCD44andCD49fLeading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance

(2010) Karen To et al.   CANCER RESEARCH

Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity

(2010) A. K. Keating et al.   MOLECULAR CANCER THERAPEUTICS

The role of insulin receptor substrate-1 in transformation by v-src

(2007) Hongzhi Sun et al.   JOURNAL OF CELLULAR PHYSIOLOGY